Source:http://linkedlifedata.com/resource/pubmed/id/18719344
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-3-2
|
| pubmed:abstractText |
The prevalence, clinical profiles and management of gastroenteropancreatic endocrine tumours (GEP) in France are not known. From August 1, 2001 to September 1, 2002, standardized records on patients with GEP were prospectively completed in 87 participating centres. The total group amounted to 668 patients (median age: 56 years, range: 12-89). WHO performance status was 0/1 for 80.2% of patients. The primary sites were the small bowel and colon (288), pancreas (211), unknown (77), stomach (33), non-digestive primary sites (24), appendix (20), rectum-anus (12), and oesophagus or cardia (3). GEP were functional in 260 patients (39%). Most pancreatic tumours were non-functional (72%). Metastatic disease was observed in 73.4% of cases. Most tumours (85.8%) were well or moderately differentiated. Somatostatin receptor scintigraphy was performed in only 55% of patients. The following treatment modalities were employed: resection of primary tumour: 66%; systemic chemotherapy: 41%; somatostatin analogues: 44 and 26% for GEP of small intestine and pancreas, respectively; interferon: 12%, and intra-arterial hepatic (chemo)embolization in 23 and 15% of GEP arising from the midgut and pancreas, respectively. Despite their low prevalence, well-differentiated GEP represent a significant and heterogeneous clinical group, which warrants improved medical education, referral to expert centres at an early stage, and the design of prospective therapeutic trials.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1423-0194
|
| pubmed:author |
pubmed-author:AparicioTT,
pubmed-author:Borson-ChazotFF,
pubmed-author:CacheuxWW,
pubmed-author:CadiotGG,
pubmed-author:ChayvialleJ AJA,
pubmed-author:DucreuxMM,
pubmed-author:EtienneP LPL,
pubmed-author:FFCD-ANGH-GERCOR,
pubmed-author:LecomteTT,
pubmed-author:LegouxJ LJL,
pubmed-author:Lombard-BohasCC,
pubmed-author:LouvetCC,
pubmed-author:MitryEE,
pubmed-author:O'TooleDD,
pubmed-author:PillonDD,
pubmed-author:RougierPP,
pubmed-author:RuszniewskiPP,
pubmed-author:SeitzJ FJF
|
| pubmed:copyrightInfo |
(c) 2008 S. Karger AG, Basel.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
89
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
217-22
|
| pubmed:meshHeading |
pubmed-meshheading:18719344-Adolescent,
pubmed-meshheading:18719344-Adult,
pubmed-meshheading:18719344-Aged,
pubmed-meshheading:18719344-Aged, 80 and over,
pubmed-meshheading:18719344-Child,
pubmed-meshheading:18719344-Female,
pubmed-meshheading:18719344-France,
pubmed-meshheading:18719344-Gastrointestinal Neoplasms,
pubmed-meshheading:18719344-Humans,
pubmed-meshheading:18719344-Male,
pubmed-meshheading:18719344-Middle Aged,
pubmed-meshheading:18719344-Neuroendocrine Tumors,
pubmed-meshheading:18719344-Pancreatic Neoplasms,
pubmed-meshheading:18719344-Registries,
pubmed-meshheading:18719344-Time Factors
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.
|
| pubmed:affiliation |
Medical Oncology, Hôpital E. Herriot, HCL Lyon, France. catherine.lombard@chu-lyon.fr
|
| pubmed:publicationType |
Journal Article,
Multicenter Study
|